CytomX Therapeutics Stock Price, News & Analysis (NASDAQ:CTMX)

$20.31 0.05 (0.25 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$20.26
Today's Range$19.98 - $20.50
52-Week Range$10.03 - $24.67
Volume202,465 shs
Average Volume271,757 shs
Market Capitalization$746.93 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics logoCytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:CTMX
  • CUSIP: N/A
  • Web: cytomx.com
Debt:
  • Current Ratio: 5.28%
  • Quick Ratio: 5.28%
Sales & Book Value:
  • Annual Sales: $15.04 million
  • Price / Sales: 51.87
  • Book Value: $1.18 per share
  • Price / Book: 17.21
Profitability:
  • Trailing EPS: ($1.57)
  • Net Income: ($58,900,000.00)
  • Net Margins: -113.64%
  • Return on Equity: -92.42%
  • Return on Assets: -20.70%
Misc:
  • Employees: 80
  • Outstanding Shares: 38,410,000
 
Frequently Asked Questions for CytomX Therapeutics (NASDAQ:CTMX)

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.05. The biotechnology company earned $3.45 million during the quarter, compared to the consensus estimate of $3.20 million. CytomX Therapeutics had a negative net margin of 113.64% and a negative return on equity of 92.42%. View CytomX Therapeutics' Earnings History.

Where is CytomX Therapeutics' stock going? Where will CytomX Therapeutics' stock price be in 2017?

10 brokerages have issued 12-month price targets for CytomX Therapeutics' shares. Their forecasts range from $24.00 to $44.00. On average, they expect CytomX Therapeutics' stock price to reach $33.00 in the next year. View Analyst Ratings for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:

  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (11/10/2017)
  • 2. Cann analysts commented, "Loss per share was $0.69, compared to our estimate of $0.56. This was the result of higher than expected R&D expense of $28.1 million compared to our estimate of $15.2 million, which resulted from a $10 million payment to UCSB for a sublicense payment. This was partially offset by higher than estimated revenue of $8.8 million compared to our estimated $1.0 million." (8/8/2017)
  • 3. Cowen and Company analysts commented, "CTMX announced that the first patient in CX-2009’s (CD166 PDC) Phase I trial has." (6/28/2017)
  • 4. HC Wainwright analysts commented, "Before the market opened on May 5, TG reported 1Q17 results. The company recently reported preliminary data from its ongoing Phase II study of TG-1101 in patients with relapsing forms of multiple sclerosis. Preliminary results indicated that TG-1101 was well tolerated with no Grade III/IV adverse events (AEs) observed and the most commonly reported AE being infusion-related reactions, with median time on study of five months. All patients achieved the primary endpoint of greater than 95% B-cell depletion by four weeks. The median B-cell depletion at week four was reported to be 99% after two infusions with a cumulative dose of 600 mg, which compares favorably to other anti-CD20 monoclonal antibodies (mAbs). Management indicated that additional data from the ongoing Phase II study will be reported later this year and that the company is on track to initiate a Phase III trial in MS in 2H17." (5/8/2017)
  • 5. Instinet analysts commented, "We are initiating on CytomX Therapeutics (CTMX) with a Buy rating and $21 12-month target price. We recommend owning CTMX shares ahead of 2H17 and 2018 data readouts for CX-072 and CX-2009, which we anticipate will validate the platforms MOA and frame breadth of utility. We remain focused on CX-072 in combo with Zelboraf, on the belief that a strong signal here will provide clear proof-of-concept for the approach, thus limiting downside risk. We look to CX-2009 as an opportunity for potentially significant upside given the high unmet need of solid tumors that express CD166. The potential for value to be ascribed to CTMX pipeline candidates presents upside potential to our estimates." (3/1/2017)

Who are some of CytomX Therapeutics' key competitors?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:

  • Hoyoung Huh Ph.D., Chairman of the Board (Age 48)
  • Sean A. McCarthy Ph.D., President, Chief Executive Officer, Director (Age 50)
  • Debanjan Ray, Chief Financial Officer, , IR Contact Officer (Age 39)
  • Cynthia Jane Ladd, Senior Vice President, General Counsel (Age 62)
  • W. Michael Kavanaugh M.D., Chief Scientific Officer and Head - Research and Non-Clinical Development (Age 60)
  • Rachel W. Humphrey M.D., Chief Medical Officer (Age 55)
  • Charles S. Fuchs M.D., Director
  • Marion McCourt, Director (Age 57)
  • John A. Scarlett M.D., Director (Age 66)
  • Neil Exter, Independent Director (Age 58)

Who owns CytomX Therapeutics stock?

CytomX Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (0.62%), Sphera Funds Management LTD. (0.55%), Private Advisor Group LLC (0.48%), American Century Companies Inc. (0.46%), Schwab Charles Investment Management Inc. (0.44%) and OxFORD Asset Management LLP (0.43%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy, Timothy M Shannon and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.

Who sold CytomX Therapeutics stock? Who is selling CytomX Therapeutics stock?

CytomX Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Strs Ohio, Russell Investments Group Ltd., California State Teachers Retirement System and JPMorgan Chase & Co.. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy and William Michael Kavanaugh. View Insider Buying and Selling for CytomX Therapeutics.

Who bought CytomX Therapeutics stock? Who is buying CytomX Therapeutics stock?

CytomX Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP, American Century Companies Inc., Private Advisor Group LLC, Allianz Asset Management GmbH, Schwab Charles Investment Management Inc., AMP Capital Investors Ltd, Dynamic Technology Lab Private Ltd and Schroder Investment Management Group. View Insider Buying and Selling for CytomX Therapeutics.

How do I buy CytomX Therapeutics stock?

Shares of CytomX Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CytomX Therapeutics stock can currently be purchased for approximately $20.31.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $746.93 million and generates $15.04 million in revenue each year. The biotechnology company earns ($58,900,000.00) in net income (profit) each year or ($1.57) on an earnings per share basis. CytomX Therapeutics employs 80 workers across the globe.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 Oyster Point Blvd Ste 400, SOUTH SAN FRANCISCO, CA 94080-1910, United States. The biotechnology company can be reached via phone at +1-650-5153185 or via email at [email protected]


MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for CytomX Therapeutics (NASDAQ:CTMX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 7 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $33.00 (62.48% upside)
Consensus Price Target History for CytomX Therapeutics (NASDAQ:CTMX)
Price Target History for CytomX Therapeutics (NASDAQ:CTMX)
Analysts' Ratings History for CytomX Therapeutics (NASDAQ:CTMX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017Cantor FitzgeraldInitiated CoverageOverweight$35.00N/AView Rating Details
10/5/2017Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
10/4/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
10/4/2017Bank of America CorporationBoost Price TargetBuy$30.00 -> $34.00HighView Rating Details
10/4/2017NomuraBoost Price TargetBuy$44.00HighView Rating Details
10/4/2017WedbushSet Price TargetBuy$26.00 -> $37.00HighView Rating Details
8/25/2017Jefferies Group LLCSet Price TargetBuy$25.00LowView Rating Details
8/8/2017CannReiterated RatingHoldHighView Rating Details
5/8/2017HC WainwrightReiterated RatingBuyLowView Rating Details
3/20/2017InstinetBoost Price TargetSell$21.00 -> $32.00MediumView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for CytomX Therapeutics (NASDAQ:CTMX)
Earnings by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Earnings History by Quarter for CytomX Therapeutics (NASDAQ CTMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.39)($0.69)$4.95 million$8.75 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.55)($0.23)$2.10 million$11.65 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.45)($0.39)$6.27 millionViewN/AView Earnings Details
11/3/2016Q3($0.35)($0.40)$3.20 million$3.45 millionViewN/AView Earnings Details
8/3/2016Q2($0.41)($0.39)$2.10 million$3.09 millionViewN/AView Earnings Details
5/6/2016Q1 2016($0.26)($0.44)$6.00 million$2.22 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CytomX Therapeutics (NASDAQ:CTMX)
2017 EPS Consensus Estimate: ($1.92)
2018 EPS Consensus Estimate: ($0.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.48)($0.48)($0.48)
Q2 20172($1.04)($0.53)($0.79)
Q3 20173($0.36)($0.01)($0.21)
Q4 20173($0.64)($0.25)($0.45)
Q1 20182($0.22)($0.01)($0.12)
Q2 20182($0.25)($0.08)($0.17)
Q3 20182($0.28)($0.14)($0.21)
Q4 20182($0.30)($0.18)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CytomX Therapeutics (NASDAQ:CTMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CytomX Therapeutics (NASDAQ CTMX)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 57.85%
Insider Trades by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Insider Trades by Quarter for CytomX Therapeutics (NASDAQ:CTMX)
Insider Trades by Quarter for CytomX Therapeutics (NASDAQ CTMX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017Debanjan RayCFOSell2,500$20.00$50,000.00View SEC Filing  
11/1/2017Sean A MccarthyCEOSell14,342$19.86$284,832.12View SEC Filing  
10/4/2017Frederick W GluckDirectorSell10,000$24.27$242,700.00View SEC Filing  
10/4/2017Robert I TepperMajor ShareholderSell24,777$24.34$603,072.18View SEC Filing  
10/4/2017Sean A MccarthyCEOSell19,120$24.13$461,365.60View SEC Filing  
10/4/2017William Michael KavanaughInsiderSell48,368$24.34$1,177,277.12View SEC Filing  
10/2/2017Debanjan RayCFOSell2,500$18.10$45,250.00View SEC Filing  
10/2/2017Sean A MccarthyInsiderSell9,562$18.57$177,566.34View SEC Filing  
9/26/2017Frederick W GluckDirectorSell5,000$17.30$86,500.00View SEC Filing  
9/19/2017Robert I TepperMajor ShareholderSell20,000$18.00$360,000.00View SEC Filing  
9/1/2017Debanjan RayCFOSell2,500$17.17$42,925.00View SEC Filing  
9/1/2017Sean A MccarthyInsiderSell9,930$17.32$171,987.60View SEC Filing  
8/31/2017Sean A MccarthyInsiderSell18,756$17.50$328,230.00View SEC Filing  
8/9/2017Debanjan RayCFOSell2,500$15.00$37,500.00View SEC Filing  
8/9/2017Sean A MccarthyInsiderSell4,781$15.00$71,715.00View SEC Filing  
7/3/2017Debanjan RayCFOSell2,500$15.47$38,675.00View SEC Filing  
7/3/2017Sean A MccarthyInsiderSell4,781$15.52$74,201.12View SEC Filing  
6/29/2017Robert I TepperMajor ShareholderSell15,000$16.00$240,000.00View SEC Filing  
6/26/2017Frederick W GluckDirectorSell5,000$14.61$73,050.00View SEC Filing  
6/26/2017Sean A MccarthyInsiderSell4,481$15.00$67,215.00View SEC Filing  
6/5/2017Sean A MccarthyInsiderSell300$15.00$4,500.00View SEC Filing  
5/1/2017Sean A MccarthyInsiderSell4,781$15.70$75,061.70View SEC Filing  
4/12/2017Kevin P StarrMajor ShareholderSell28,357$16.36$463,920.52View SEC Filing  
4/4/2017Sean A MccarthyInsiderSell9,562$17.22$164,657.64View SEC Filing  
3/27/2017Rock Ventures Lp ThirdMajor ShareholderSell1,650,000$17.39$28,693,500.00View SEC Filing  
3/20/2017Robert C Goeltz IICFOSell21,517$19.81$426,251.77View SEC Filing  
3/20/2017Sean A MccarthyInsiderSell14,343$19.60$281,122.80View SEC Filing  
3/3/2017Sean A MccarthyInsiderSell14,343$15.00$215,145.00View SEC Filing  
11/28/2016Ix L.P. CanaanDirectorSell38,459$11.56$444,586.04View SEC Filing  
11/22/2016Ix L.P. CanaanDirectorSell42,550$11.71$498,260.50View SEC Filing  
11/21/2016Ix L.P. CanaanDirectorSell45,324$11.61$526,211.64View SEC Filing  
11/16/2016Ix L.P. CanaanDirectorSell51,581$11.50$593,181.50View SEC Filing  
11/15/2016Timothy M ShannonDirectorSell33,064$11.48$379,574.72View SEC Filing  
11/14/2016Ix L.P. CanaanDirectorSell86,270$11.16$962,773.20View SEC Filing  
11/9/2016Ix L.P. CanaanDirectorSell13,730$11.03$151,441.90View SEC Filing  
6/10/2016Timothy M ShannonDirectorSell48,427$10.07$487,659.89View SEC Filing  
6/7/2016Ix L.P. CanaanDirectorSell111,498$10.01$1,116,094.98View SEC Filing  
6/3/2016Ix L.P. CanaanDirectorSell59,621$10.80$643,906.80View SEC Filing  
6/1/2016Ix L.P. CanaanDirectorSell22,463$10.75$241,477.25View SEC Filing  
5/27/2016Ix L.P. CanaanDirectorSell25,082$10.60$265,869.20View SEC Filing  
5/26/2016Timothy M ShannonDirectorSell51,343$10.34$530,886.62View SEC Filing  
5/24/2016Ix L.P. CanaanDirectorSell13,253$10.09$133,722.77View SEC Filing  
5/20/2016Ix L.P. CanaanDirectorSell8,687$10.10$87,738.70View SEC Filing  
10/14/2015Cynthia J LaddVPBuy3,000$12.00$36,000.00View SEC Filing  
10/14/2015Frederick W GluckDirectorBuy15,000$12.00$180,000.00View SEC Filing  
10/14/2015James E FlynnInsiderBuy625,000$12.00$7,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CytomX Therapeutics (NASDAQ:CTMX)
Latest Headlines for CytomX Therapeutics (NASDAQ CTMX)
Source:
DateHeadline
CytomX Therapeutics, Inc. (CTMX) Receives Consensus Rating of "Hold" from BrokeragesCytomX Therapeutics, Inc. (CTMX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 13 at 9:36 PM
CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017CytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 13 at 8:49 PM
CytomX Therapeutics, Inc. (CTMX) Expected to Announce Quarterly Sales of $10.70 MillionCytomX Therapeutics, Inc. (CTMX) Expected to Announce Quarterly Sales of $10.70 Million
www.americanbankingnews.com - November 11 at 7:00 AM
Zacks Investment Research Downgrades CytomX Therapeutics, Inc. (CTMX) to HoldZacks Investment Research Downgrades CytomX Therapeutics, Inc. (CTMX) to Hold
www.americanbankingnews.com - November 10 at 9:20 PM
Oppenheimer Holdings Comments on CytomX Therapeutics, Inc.s Q4 2017 Earnings (CTMX)Oppenheimer Holdings Comments on CytomX Therapeutics, Inc.'s Q4 2017 Earnings (CTMX)
www.americanbankingnews.com - November 10 at 9:04 AM
Wedbush Comments on CytomX Therapeutics, Inc.s FY2017 Earnings (CTMX)Wedbush Comments on CytomX Therapeutics, Inc.'s FY2017 Earnings (CTMX)
www.americanbankingnews.com - November 10 at 7:47 AM
FY2017 EPS Estimates for CytomX Therapeutics, Inc. Reduced by Analyst (CTMX)FY2017 EPS Estimates for CytomX Therapeutics, Inc. Reduced by Analyst (CTMX)
www.americanbankingnews.com - November 10 at 7:47 AM
FY2017 EPS Estimates for CytomX Therapeutics, Inc. Reduced by Analyst (CTMX)FY2017 EPS Estimates for CytomX Therapeutics, Inc. Reduced by Analyst (CTMX)
www.americanbankingnews.com - November 10 at 7:47 AM
-$0.42 EPS Expected for CytomX Therapeutics, Inc. (CTMX) This Quarter-$0.42 EPS Expected for CytomX Therapeutics, Inc. (CTMX) This Quarter
www.americanbankingnews.com - November 9 at 3:52 PM
ETFs with exposure to CytomX Therapeutics, Inc. : November 8, 2017ETFs with exposure to CytomX Therapeutics, Inc. : November 8, 2017
finance.yahoo.com - November 8 at 11:26 PM
CytomX Announces Third Quarter 2017 Financial Results and Operational ProgressCytomX Announces Third Quarter 2017 Financial Results and Operational Progress
finance.yahoo.com - November 8 at 12:35 AM
Insider Selling: CytomX Therapeutics, Inc. (CTMX) CFO Sells 2,500 Shares of StockInsider Selling: CytomX Therapeutics, Inc. (CTMX) CFO Sells 2,500 Shares of Stock
www.americanbankingnews.com - November 3 at 6:30 PM
Sean A. Mccarthy Sells 14,342 Shares of CytomX Therapeutics, Inc. (CTMX) StockSean A. Mccarthy Sells 14,342 Shares of CytomX Therapeutics, Inc. (CTMX) Stock
www.americanbankingnews.com - November 3 at 5:46 PM
CytomX to Present at the Jefferies 2017 London Healthcare ConferenceCytomX to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 1 at 6:31 PM
CytomX Therapeutics to Announce Third Quarter 2017 Financial ResultsCytomX Therapeutics to Announce Third Quarter 2017 Financial Results
finance.yahoo.com - October 26 at 7:35 PM
Analysts Set Expectations for CytomX Therapeutics, Inc.s FY2017 Earnings (CTMX)Analysts Set Expectations for CytomX Therapeutics, Inc.'s FY2017 Earnings (CTMX)
www.americanbankingnews.com - October 26 at 9:57 AM
CytomX Therapeutics, Inc. (CTMX) to Release Quarterly Earnings on WednesdayCytomX Therapeutics, Inc. (CTMX) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:52 AM
BRIEF-CytomX Therapeutics appoints Charles Fuchs to board of directorsBRIEF-CytomX Therapeutics appoints Charles Fuchs to board of directors
www.reuters.com - October 25 at 1:02 AM
CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of DirectorsCytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors
finance.yahoo.com - October 24 at 8:00 PM
CytomX Therapeutics, Inc. (CTMX) Coverage Initiated at Cantor FitzgeraldCytomX Therapeutics, Inc. (CTMX) Coverage Initiated at Cantor Fitzgerald
www.americanbankingnews.com - October 23 at 6:20 PM
CytomX Therapeutics, Inc. (CTMX) Expected to Announce Quarterly Sales of $16.60 MillionCytomX Therapeutics, Inc. (CTMX) Expected to Announce Quarterly Sales of $16.60 Million
www.americanbankingnews.com - October 22 at 3:52 AM
CytomX Therapeutics, Inc. (CTMX) Expected to Post Earnings of -$0.11 Per ShareCytomX Therapeutics, Inc. (CTMX) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - October 20 at 8:28 PM
CytomX Therapeutics, Inc. (CTMX) Receives Consensus Rating of "Hold" from AnalystsCytomX Therapeutics, Inc. (CTMX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 19 at 9:38 PM
CytomX Therapeutics, Inc. (CTMX) Stock Rating Upgraded by Zacks Investment ResearchCytomX Therapeutics, Inc. (CTMX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 16 at 9:24 PM
Contrasting Akari Therapeutics PLC (AKTX) & CytomX Therapeutics (CTMX)Contrasting Akari Therapeutics PLC (AKTX) & CytomX Therapeutics (CTMX)
www.americanbankingnews.com - October 16 at 2:11 AM
Short Interest Expands By 26.7% For CTMXShort Interest Expands By 26.7% For CTMX
www.thestreet.com - October 11 at 4:40 PM
Your Daily Pharma Scoop: Synergys Cash Position, Flexions Zilretta Approval, Keryx Major CatalystYour Daily Pharma Scoop: Synergy's Cash Position, Flexion's Zilretta Approval, Keryx Major Catalyst
seekingalpha.com - October 10 at 3:21 PM
Analysts’ Recommendations for Amgen in October 2017Analysts’ Recommendations for Amgen in October 2017
finance.yahoo.com - October 9 at 3:14 PM
Cancer Space Last Week Update: Pipeline Expansion in FocusCancer Space Last Week Update: Pipeline Expansion in Focus
finance.yahoo.com - October 9 at 3:13 PM
Wedbush Analysts Give CytomX Therapeutics, Inc. (CTMX) a $37.00 Price TargetWedbush Analysts Give CytomX Therapeutics, Inc. (CTMX) a $37.00 Price Target
www.americanbankingnews.com - October 8 at 11:14 PM
CytomX Therapeutics, Inc. (CTMX) Price Target Raised to $44.00 at NomuraCytomX Therapeutics, Inc. (CTMX) Price Target Raised to $44.00 at Nomura
www.americanbankingnews.com - October 8 at 6:40 PM
Sean A. Mccarthy Sells 19,120 Shares of CytomX Therapeutics, Inc. (CTMX) StockSean A. Mccarthy Sells 19,120 Shares of CytomX Therapeutics, Inc. (CTMX) Stock
www.americanbankingnews.com - October 6 at 7:26 PM
CytomX Therapeutics, Inc. (CTMX) Director Sells $242,700.00 in StockCytomX Therapeutics, Inc. (CTMX) Director Sells $242,700.00 in Stock
www.americanbankingnews.com - October 6 at 1:20 PM
CytomX Therapeutics, Inc. (CTMX) Insider William Michael Kavanaugh Sells 48,368 SharesCytomX Therapeutics, Inc. (CTMX) Insider William Michael Kavanaugh Sells 48,368 Shares
www.americanbankingnews.com - October 6 at 1:20 PM
Q3 2017 EPS Estimates for CytomX Therapeutics, Inc. Cut by Analyst (CTMX)Q3 2017 EPS Estimates for CytomX Therapeutics, Inc. Cut by Analyst (CTMX)
www.americanbankingnews.com - October 6 at 7:42 AM
CytomX Therapeutics, Inc. (CTMX) Receives Outperform Rating from Cowen and CompanyCytomX Therapeutics, Inc. (CTMX) Receives Outperform Rating from Cowen and Company
www.americanbankingnews.com - October 5 at 1:32 PM
Amgen, CytomX Join in Immuno-Oncology CollaborationAmgen, CytomX Join in Immuno-Oncology Collaboration
finance.yahoo.com - October 5 at 10:48 AM
CytomX Therapeutics Inc. (CTMX) Jumped To A New High On Amgen CollaborationCytomX Therapeutics Inc. (CTMX) Jumped To A New High On Amgen Collaboration
www.rttnews.com - October 5 at 10:48 AM
CytomX Therapeutics, Inc. Forecasted to Earn Q1 2018 Earnings of ($0.21) Per Share (CTMX)CytomX Therapeutics, Inc. Forecasted to Earn Q1 2018 Earnings of ($0.21) Per Share (CTMX)
www.americanbankingnews.com - October 5 at 10:40 AM
CytomX Therapeutics, Inc. (CTMX) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.CytomX Therapeutics, Inc. (CTMX) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 4 at 11:44 PM
CytomX Therapeutics, Inc. (CTMX) Insider Sells $177,566.34 in StockCytomX Therapeutics, Inc. (CTMX) Insider Sells $177,566.34 in Stock
www.americanbankingnews.com - October 4 at 10:24 PM
CytomX Therapeutics, Inc. (CTMX) Expected to Post Quarterly Sales of $17.27 MillionCytomX Therapeutics, Inc. (CTMX) Expected to Post Quarterly Sales of $17.27 Million
www.americanbankingnews.com - October 4 at 9:32 PM
Insider Selling: CytomX Therapeutics, Inc. (CTMX) Major Shareholder Sells 24,777 Shares of StockInsider Selling: CytomX Therapeutics, Inc. (CTMX) Major Shareholder Sells 24,777 Shares of Stock
www.americanbankingnews.com - October 4 at 7:40 PM
Bank of America Corporation Boosts CytomX Therapeutics, Inc. (CTMX) Price Target to $34.00Bank of America Corporation Boosts CytomX Therapeutics, Inc. (CTMX) Price Target to $34.00
www.americanbankingnews.com - October 4 at 2:02 PM
Pre-Open Stock Movers 10/04: (CTMX) (CATB) (MYL) Higher; (CLSN) (MNTA) (TEVA) (ODP) Lower (more...)Pre-Open Stock Movers 10/04: (CTMX) (CATB) (MYL) Higher; (CLSN) (MNTA) (TEVA) (ODP) Lower (more...)
www.streetinsider.com - October 4 at 11:31 AM
CytomX Therapeutics Inc. (CTMX) Has Jumped To A New High On Amgen NewsCytomX Therapeutics Inc. (CTMX) Has Jumped To A New High On Amgen News
www.nasdaq.com - October 4 at 11:31 AM
Amgen Enters Into an Immuno-Oncology Partnership With CytomXAmgen Enters Into an Immuno-Oncology Partnership With CytomX
finance.yahoo.com - October 4 at 11:31 AM
CytomX Therapeutics Inc. (CTMX) Is Climbing On Amgen Collaboration NewsCytomX Therapeutics Inc. (CTMX) Is Climbing On Amgen Collaboration News
www.rttnews.com - October 3 at 5:29 PM
ETFs with exposure to CytomX Therapeutics, Inc. : October 3, 2017ETFs with exposure to CytomX Therapeutics, Inc. : October 3, 2017
finance.yahoo.com - October 3 at 5:29 PM
Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-OncologyAmgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology
finance.yahoo.com - October 3 at 5:29 PM

Social Media

Financials

Chart

CytomX Therapeutics (NASDAQ CTMX) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.